BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Rheumatoid arthritis clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for rheumatoid arthritis: 212 (111 sponsors; 27 newly posted in the last 180 days, 8 stopped in the last 180 days; 14 new-entrant sponsors). Momentum score 9.4, rank 74 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 7, Phase 1 51, Phase 2 41, Phase 3 18, Phase 4 0, N/A 95.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Bristol-Myers Squibb BMY8NA 1, P3 4, P1 2, P2 121
Novartis Pharmaceuticals NVS9P2 3, P3 3, NA 1, P1 231
Amgen AMGN3P2 1, P3 200
AbbVie ABBV6P2 2, P1 2, NA 1, P3 121
SetPoint Medical Corporation3P3 1, NA 201
Hangzhou Highlightll Pharmaceutical Co., Ltd2P2 1, P3 111
Beijing VDJBio Co., LTD.1P3 100
Biocad1P3 100
Janssen Research & Development, LLC1P3 101
Jiankuan (Suzhou) Biotechnology Company Limited new entrant1P3 111
Swedish Orphan Biovitrum1P3 100
Vor Biopharma VOR1P3 100
Zimmer Biomet ZBH24NA 2406
MicroPort Orthopedics Inc.10NA 1000
Medacta International SA9NA 900
Aesculap AG5NA 500
AstraZeneca AZN4P2 2, P1 201
China Immunotech (Beijing) Biotechnology Co., Ltd.4P1 3, NA 102
Stryker Trauma and Extremities SYK4NA 400
Changchun GeneScience Pharmaceutical Co., Ltd.3P2 2, P1 100
Exactech3NA 300
Merck Sharp & Dohme LLC MRK3P2 2, P1 110
Candid Therapeutics2P1 210
Cullinan Therapeutics Inc. CGEM2P1 200
Eli Lilly and Company LLY2P1 200

New-entrant sponsors: Jiankuan (Suzhou) Biotechnology Company Limited.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12 est.P2Toll Biotech Co. Ltd. (Beijing)NCT07408024 Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid ArthritisRheumatoid Arthritis (RA)recruiting24
2026-12-31 est.P3Hangzhou Highlightll Pharmaceutical Co., LtdNCT06887127 A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid ArthritisRheumatoid Arthritisactive not recruiting350
2027-01-15 est.P2XBiotech, Inc. XBITNCT06590090 Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentRheumatoid Arthritisnot yet recruiting108
2027-02 est.P2AbbVie ABBVNCT06972446 A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisRheumatoid Arthritisrecruiting180

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-31 est.P2Spyre Therapeutics, Inc. SYRENCT07148414 A Study of SPY072 in Rheumatic DiseaseRheumatoid Arthritis; Psoriatic Arthritis; Axial Spondyloarthritis; Rheumatic Diseases; Rheumatic Joactive not recruiting285
2026-09-07P2Merck Sharp & Dohme LLC MRKNCT07176390 A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)Arthritis, Rheumatoidactive not recruiting185
2026-07-15P3AbbVie ABBVNCT05814627 Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to SeRheumatoid Arthritiscompleted487
2026-07-02P2Citryll BVNCT06567470 A Study With CIT-013 in RA PatientsRheumatoid Arthritiscompleted96

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "rheumatoid arthritis"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.